CKM Syndrome - Nephrology Lectures 2025

What CKM syndrome actually claims. Obesity, dysglycemia, chronic kidney disease and cardiovascular disease are not four illnesses that happen to co-occur. They are one pathophysiologic continuum with shared mediators and shared therapeutic targets — and a patient's position along that continuum predicts absolute cardiovascular risk better than counting discrete risk factors.

📋 Why the 2026 guideline matters

The staging construct began as the 2023 AHA presidential advisory. The 2026 AHA/ACC/ADA/ASN guideline converts that advisory into a graded clinical practice guideline with formal COR/LOE recommendations, extends it across the life course, and retires and replaces the 2013 AHA/ACC/TOS obesity guideline.

For nephrology, one structural fact outranks the rest. ASN is a full endorsing society alongside ADA and the Obesity Association. CKD is not a downstream complication in this framework — it is a staging axis of equal standing with adiposity and dysglycemia, and very-high-risk CKD is treated as a cardiovascular risk equivalent in its own right. Nephrology is embedded in the framework rather than consulted by it.

🎯 The five stages at a glance

Stage 0No CKM syndrome. Normal weight, glucose, BP, lipids and kidney function; no subclinical or clinical CVD. Primordial prevention.

Stage 1Excess or dysfunctional adiposity, and/or prediabetes. No other metabolic risk factors, no CKD, no CVD.

Stage 2Metabolic risk factors and/or CKD — type 2 diabetes, hypertension, hypertriglyceridemia, metabolic syndrome, moderate-to-high-risk CKD.

Stage 3Subclinical CVD, or a CKM risk equivalent — very-high-risk CKD, or 10-year PREVENT-CVD risk at or above 20%.

Stage 4Clinical CVD. Substaged 4a (no kidney failure) and 4b (eGFR below 15 or chronic kidney replacement therapy).

Stage 4 is not "any coronary disease." A coronary calcium score of 900 without events is stage 3. A prior PCI is stage 4 even in a currently asymptomatic patient. The line is clinical events or revascularization — not atherosclerotic burden. Symptomatic heart failure at any ejection fraction qualifies, as does atrial fibrillation on its own, with no ischemic or structural disease required.

🧠 The one-sentence version

CKM staging answers "how aggressively do I treat cardiovascular risk, and with which agents?" It does not answer "how fast will this kidney fail?" Conflating the two is the most common misuse of the framework — and it is why the CKM versus KFRE deep dive exists.

📈 PREVENT — the risk engine underneath

PREVENT estimates 10- and 30-year risk of ASCVD, heart failure and total CVD, and takes eGFR and optionally UACR and HbA1c directly as inputs. It is recommended in stages 0–3; in stage 4 the patient already has clinical disease and prediction is superseded by secondary prevention.

Threshold	Action
PREVENT-CVD 10-year at or above 7.5%	Prioritize pharmacotherapy
PREVENT-CVD 10-year at or above 20%	Meets a stage 3 criterion as a risk equivalent
PREVENT-HF 10-year at or above 5% in prediabetes or T2D	Obtain natriuretic peptide with or without hs-troponin; image if elevated

💊 Therapy by stage

Stage	Architecture
1	Lifestyle as the foundation; obesity pharmacotherapy and metabolic/bariatric surgery as adjuncts, explicitly framed as tools to prevent progression and promote stage regression. First guideline to endorse GLP-1-based therapy for cardiovascular event reduction in selected patients with obesity, with or without T2D.
2	Metabolic: GLP-1-based agent or SGLT2 inhibitor with proven benefit when PREVENT-CVD is at or above 7.5%, or age over 50 with added risk factors. Metformin is adjunctive — layered onto cardioprotective agents rather than preceding them. Kidney: measure eGFR and UACR; RASi plus SGLT2i first-line.
3	Same architecture, intensified. Combination SGLT2i plus GLP-1-based therapy may be considered. Very-high-risk CKD alone qualifies — treat it as a CVD risk equivalent, not a kidney problem awaiting a cardiac indication.
4	ASCVD plus T2D: at least one agent with proven CV benefit in all patients. HFrEF: RASi (ARNI preferred), beta blocker, steroidal MRA, SGLT2i. HFmrEF/HFpEF: SGLT2i first-line. Obesity and kidney-protective therapy continue in parallel.

Persistent albuminuria on first-line therapy

Add-on	Threshold	Favored when
Finerenone	UACR at or above 30 mg/g	Normokalemic, albuminuria-predominant phenotype
Semaglutide	UACR at or above 100 mg/g	Obesity, uncontrolled diabetes, or MASLD present

SGLT2i is the first-line cardioprotective antihyperglycemic in T2D with heart failure or CKD, and is initiable down to eGFR 20 mL/min/1.73 m².

📚 Deep dives

🧬 Staging and the kidney axis ⚖️ CKM staging vs KFRE 🧪 Glycemic management in CKD

🪶 Nephrology-specific traps

Euglycemic DKA

Relative insulinopenia plus SGLT2i is the classic setup. At HbA1c above 10% with catabolic features, establish insulin before or alongside the SGLT2i.

eGFR floors

SGLT2i initiation down to eGFR 20 with continuation thereafter. Metformin contraindicated below 30. Finerenone requires potassium surveillance. GLP-1 RA dosing is not eGFR-adjusted.

Cardiorenal indication is not glycemic control

SGLT2i retains cardiorenal benefit to eGFR 20 but is not a glucose-lowering agent at G4. Do not let the cardiorenal indication substitute for glycemic management.

Dialysis (stage 4b)

HbA1c has low reliability, pre-HF biomarker cut points are uninterpretable, and PREVENT is not applicable. Three of the framework's instruments go dark at once.

Where implementation will actually fail. The guideline's structural recommendations — a named CKM coordination point person, routine social-determinants screening, and selected screening for pre-HF, MASLD and OSA — are the operational core. They are also the parts most health systems will not build.

🔍 Source and verification

Primary source: the 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome (Circulation. 2026;154(4):e50–e158, PMID 42263157), published Free Access and read in full for these pages. Glycemic triggers are from the ADA Standards of Care in Diabetes — 2026, Section 9 (PMID 41358900), read in full via PubMed Central. Kidney staging and glycemic targets in CKD are from KDIGO 2024 and KDIGO 2022 (PMID 36272764), the latter verified against its peer-reviewed synopsis (PMID 36623286).

Every numeric threshold on this page was checked against the source text. Figures that could not be confirmed in a primary source were removed rather than published with a caveat — including a set of pre-HF biomarker cut points that circulate in secondary summaries but appear nowhere in the guideline.

📚 Key references

Ndumele CE, Rodriguez F, Dixon DL, et al. 2026 AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome. Circulation. 2026;154(4):e50–e158. PMID 42263157.
Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the AHA. Circulation. 2023;148(20):1606–1635. PMID 37807924.
Khan SS, Matsushita K, Sang Y, et al. Development and validation of the AHA's PREVENT equations. Circulation. 2024;149(6):430–449. PMID 37947085.
Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on CKD outcomes in type 2 diabetes (FIDELIO-DKD). N Engl J Med. 2020;383(23):2219–2229. PMID 33264825.
Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on CKD in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109–121. PMID 38785209.

❤️ CKM Syndrome